Legal
Fifth Circuit to Hear Mifepristone Access Case Amid Medicaid Coverage Implications
A three-judge panel on the Fifth Circuit Court of Appeals will hear oral arguments in a case challenging nationwide distribution of mifepristone, the medication abortion drug. The case could result in restrictions on mifepristone access that would affect Medicaid beneficiaries and state Medicaid pharmacy programs. Oral arguments are scheduled for next week, with a decision timeline uncertain. The outcome could require state Medicaid agencies and managed care plans to adjust pharmacy benefits, provider networks, and utilization management protocols for medication abortion services covered under Medicaid.
Why it mattersA Fifth Circuit ruling restricting mifepristone distribution would force state Medicaid agencies and MCOs to modify pharmacy benefits and potentially increase reliance on procedural abortion coverage, affecting service delivery and costs for reproductive health services under Medicaid.